Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would hope that the City (New York)purchased the 100,000 units. If not, this is of serious concern.
It is clear to me that the company has not had anything to do with PSC's coverage. The problem right now is that, as is typical with these low priced stocks, they are fodder for day traders and quick swing artists. We simply need more true long term investors who believe in the company and product. We should be helped on that front over the next days and weeks.
Slo - it is very common in companies of this size and at this stage to have all of the insider stock or company-held stock restricted for an extended period. I own shares in several companies where this is the case. Bottom line: I have no reason to conclude that IR was anything less than completely truthful in response to my very specific inquiries.
Clarification from IR: I contacted Investor Relations (IR) for UTRM to inquire as to the representations on this Board regarding Penny Stock Chaser (PSC). According to IR, the company, its management, and insiders at the company emphatically deny that the company or any current manager or insider has in any way paid PSC to promote the stock. And, IR states that neither the company or any current manager or insider has or is selling stock at this time. In fact, all management held stock is restricted and cannot be sold. IR added that they welcome the exposure for the stock and the company since in the very near future there is a considerable flow of information and Press Releases expected to be issued.
Apparently, if someone is paying PSC to promote the stock, it is not the company or any current insider doing it. I also asked whether there was any media interest in the company or product in connection with the current show and ADA meeting in New York. IR stated that they have been contacted by newspaper, TV and radio media in the New York area, and have conducted several interviews already this week. IR cautions that they have no contrlol over what any respective media report or how they cover the events in New York.
My view is this: Regardless of where the stories or promotion come form, any exposure is good exposure.
Slo: You apparently discount any benefit from the fact that this is the week that has been pointed to for some time when UTRM would get traction from the unveiling of the product at the ADA Convention and product show in New York, and the surrounding coverage which may generate interest, but not necessarily PR's from the company. I think there are other factors also at work here, but appreciate you pointing out the PSC issues.
Disappointing to see so much selling into the early rally this morning. Volume has quieted down now and bid is at .072. We need a more sustained trade above .08 - .085 for a true breakout.
Going the wrong way right now. The current Bid is .063, equal to the low trade of the day. We need to get the sellers cleared out.
Serious breakout point appears to be at .085.
Nice news this morning on European distribution network and alliances:
Competitive Technologies Announces European Regional DistributorNovember 30, 2009 9:52 AM ET
All GlobeNewswire newsFAIRFIELD, Conn., Nov. 30, 2009 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that its Geneva, Switzerland-based distributor, Life Episteme SARL, has established a joint venture, Life Episteme Italia srl, with Florence, Italy-based Hospital Consulting SpA, to distribute CTT's pain therapy medical device, Calmare(R) Therapy Treatment throughout Italy.
"Life Episteme is eager to embark on this joint venture with Hospital Consulting, which is well known in the Italian healthcare sector," said Life Episteme co-founder Dr. Domenico Pecorini. "This agreement with Hospital Consulting finalizes the first of several regional joint ventures we have in negotiation as part of our strategy for distributing CTT's innovative Calmare(R) Therapy Treatment in the global marketplace."
"Hospital Consulting has the infrastructure in place, and has extensive experience working with healthcare providers throughout Italy," said John B. Nano, CTT's Chairman, President and CEO. "We're pleased to have them join the distribution team for our Calmare(R) Therapy Treatment, which has already successfully treated more than 3,000 patients in Europe and the U.S.
"Pain treatment is moving to the forefront of medical care, globally. In Italy, Europe's largest university, La Sapienza of Rome, will prominently feature our Calmare(R) Therapy Treatment at its newly-established medical school dedicated to the treatment of pain. Hospital Consulting's recognition of important trends in healthcare confirms our belief that the ability to help patients with debilitating pain by using our non-invasive pain therapy treatment device is an attractive alternative for physicians who may be reluctant to prescribe powerful, addictive narcotics that have been linked to harmful, potentially fatal, adverse side effects.
"Recently, the University of Chicago Medical Center announced that, '... a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.' This makes the rapid introduction of our Calmare(R) Therapy Treatment into the global healthcare marketplace even more compelling. In fact, similar to the Hippocratic Oath, a fundamental principle taught to all medical students is 'Primum Non Nocere,' meaning, 'First, do no harm.'"
The Calmare(R) Therapy Treatment is a prime example of CTT's strategy to connect clinical science to patient care. Developed in Italy by CTT's client, Professor Giuseppe Marineo, the device was brought to CTT through the efforts of the Zangani Investor Community(TM) and with the cooperation of Mr. Guiseppe Belcastro, Legal Counsel for Professor Marineo. The device, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. CTT has exclusive worldwide rights to the Calmare(R) Therapy Treatment which has U.S. FDA acceptance and Medical Device CE Mark certification from the E.U. allowing sales throughout the U.S., Europe and several other countries. CTT partner, GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution. Several distribution agreements, including the one with Life Episteme, are in place covering 45 countries around the world, accounting for nearly 55% of the world's population. For more information on the device, visit www.CalmareTT.com.
About Hospital Consulting, SpA
Based in Florence, Italy, Hospital Consulting SpA provides advisory, management and organizational services to the healthcare and environment sectors. Hospital Consulting provides hospitals and other health care providers throughout Italy with valuable training, facility design and development as well as innovative risk assessment and information technology solutions. For more information, see Hospital Consulting's website: www.hospital-consulting.it.
About Life Episteme SARL
The privately held Life Episteme SARL based in Geneva, Switzerland, is a medical device distribution company. The experience of the co-founders, Dr. Domenico Pecorini, Vincenzo de Bustis Figarola, and Paolo Pepe, has provided the group with strong relationships in government, business, and technology spheres in various countries around the world. Visit Dr. Pecorini's website: www.scienceparkrome.eu.
About Life Episteme Italia, srl
This newly formed Joint Venture will benefit from the know-how and contacts of both Hospital Consulting (HC) and Life Episteme SARL group (LEG). The success of the operation will be pursued sharing competencies and dedicating high-profile resources. LEG will bring strong relationships, financial services and internationalization to the partnership. HC will provide decades of presence, success and experience in the market. The President of Life Episteme Italia (LEI) will be Dott.ssa Marisa Giampaoli, Managing Director of Hospital Consulting group, who is well respected at the highest levels of the Italian public and private health sector. Umberto Marangoni, the Country General Manager for Hospital Consulting, will serve as LEI's Managing Director. Before becoming the Country General Manager, he worked many years in the same positions in Italy and abroad, for Ohmeda and Draeger Medical, the world leaders in Anesthesia and Critical Care. LEI and the Italian activities will become fully operational beginning January 1, 2010.
About Zangani Investor Community(TM)
The Zangani Investor Community(TM) was created to facilitate scientific and commercial relationships between American, European and Chinese entities. Visit Zangani's website: www.zangani.com.
About Professor Guiseppe Marineo
Professor Guiseppe Marineo is a researcher and bioengineer, who advanced theories to reformulate the concept of disease and the corresponding treatment from a biophysical rather than a biochemical point of view. He is the founder of Delta R&D, a bioengineering research center with a unique history. Visit Delta R&D's website: www.deltard.com/eng.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
CONTACT: IR Services, LLC
Johnnie D. Johnson
860 434 2465
jdjohnson@corpirservices.com
GlobeNewswire, Inc.2009
Yes. Yes. Yes. But, I will feel better when this volume gets the stock back up between .074 and .08 like it was a while back. I could see the volume staying up for several days now with the ADA meeting, etc.
Interesting trading in AXTG today. 500 shares went through early at .09, but then all the rest of the volume was at .15
AXIS TECHNOLOGIES GR - Nasdaq: AXTG
Time & Sales most recent next page
Rec. Time Action Price Volume
10:02:23 AM Trade 0.15 100
10:01:51 AM Trade 0.15 1100
10:01:51 AM Trade 0.15 2900
9:30:13 AM Trade 0.09 500
most recent next page
4:50:56 PM EST - Tuesday, November 24, 2009 - data is delayed 20 minutes
Q: Are you nuts? Your post makes no sense. Yesterday (11/23) the bulk of the volume went through at .15. In fact, the first 26,500 shares of volume was at .15 before there were any trades below that level. Please don't try to mislead people on this Board like that.
Yes. And, World Market Media is one of the better investing blog sites. I believe it has a pretty decent following.
It looks like the real time ask may have dropped below .20 Moxa. But, what I find interesting is the fact that it traded up to .20 on very low volume, which may mean there are not as many sellers out there right now. I would, of course rather see a lot of volume to the upside, but there may be an indication of fewer sellers in this.
Amen Snackman! This is nice. I held WAVX back in the 90's and actually rode it from $20 to $50 (only stayed above $50 for a few days) and was too stupid to get out before the tech bubble buurst. But, I have a nice position now with a PPS around $2.14, and have been patiently waiting for this time for years. I think this thinig has really turned the corner. As for those posters who think WAVX will close under $1 by years end......Phooey!
Think it may have been one seller with large positions who had to get out.
I'll take some movement, and also believe there is a timely opportunity here. But, I already added to my position the week of 11/9 in the .13 range. I believe there is a good chance for something positive here in the coming weeks.
It would appear that this thing is pretty much dead for now. At least until the ADA mtg. in new York week after next, or unless some other news develops.
NNI: +30% in last month. Strong momentum - very low PE going forward, and reinstated dividend.
UTRM - Take a look. New AquaFree (waterless) toothbrush. Set to be unveiled at Amer. Dental Assn. show and conference in New York week after next. Material from World Market Media:
UTRM on WorldMarketMedia--now, if when they come out with some news, UTRM at least has a crowd watching or following it to some degree.
UTRM.PK United Treatment Centers Last $0.07 $9M (MarketCap)
Editors Desk
Date: November 11, 2009 1:51 PM
Publisher: Editors Desk
Tags: Consumer Goods, Pink Sheets
I love disruptive technology in the consumer space because the big dogs need to scramble and usually some biz dev guy gets his butt fired for not paying attention. Then some small stock explodes and large cap companies must overpay. It happens regularly to the benefit of early investors. And this profitable phenomenon seems to be on the brink in Dental Care. . I don’t want to be William Addis and I don’t want to cause a riot because I like my house on the 16th Tee Box. I just think we should stop rubbing rags on our teeth….see below.
The toothbrush is one of mans’ purest inventions, and singularly has extended lives of men and women. William Addis of England is credited with creating the first mass-produced toothbrush in 1780. In 1770 he had been placed in jail for causing a riot. While in prison, he decided that the method for teeth brushing of the time – rubbing a rag on one's teeth with soot and salt – could be improved. So he took a small animal bone, drilled small holes in it, obtained some bristles from a guard, tied them in tufts, then passed the bristles through the holes on the bone and glued them. He soon became very wealthy. Simple ideas converting to great margins.
Tooth powders for use with toothbrushes came into general use in the 19th century in Britain. Most were homemade, with chalk, pulverized brick, or salt as ingredients. An 1866 Home Encyclopedia recommended pulverized charcoal, and cautioned that many patented tooth powders that were commercially marketed did more harm than good. Recently, homemade tooth powders are made by mixing 3 parts baking soda (cleanser) thoroughly with 1 part salt (the abrasive). It seems it is time for modern dental care to make a step forward and it surely lies in the combination of brush and paste.
According to studies published by the American Dental Association- Liquid Dentifrice cleans teeth 35% better than pastes…so I went looking for a start-up company in my niche and found United Treatment Centers UTRM.PK and spent some time with the company. It seems that the “buy versus build” with Colgate and is in progress.
The right company can cause a disruptive technology to occur, and it is a classic “Give them the razor, then sell them blades forever” idea.
Provide the proprietary toothbrush with the proprietary dentifrice cartridge and—walah!—you have recurring revenues like Gillette enjoys…and this story launches November 29th, 2009 at the Greater New York Dental Meeting when UTRM.PK introduces the waterless toothbrush to the market
We created a Video called CEO Snapshot.
http://www.worldmarketmedia.com/home/video/vod-newswire-podcasts.aspx
Here is their website:
http://www.aquafreetoothbrush.com/benefits.php
We were not compensated for this review of the company. It came via a long time IR relationship who knows I like these kinds of stories. So as normal…follow along as we watch them grow…just remember where you heard it first!!!
United Treatment Centers, Inc. (UTRM) Stock Trading Info:
Thanks. CTT popped up today after that report.
Did you have a chance to look at the report I posted on CTT this morning? It had a nice move today +3.5%
This looks good.
CTT: great release from seekingalpha overnight:
CTT's Pain Mangement Device Sales to Result in Positive Surprise in 10Q (Filing Expected by Dec. 15)
Competitive Technologies, Inc. (NYSE Amex: CTT) trading at $2.03 as of 17 Nov.. may be poised to report a rapidly increasing revenue stream from their non-invasive chronic pain management medical device (Calmare TT) which received 501-k clearance from the FDA for marketing in the US recently. Compared to a Fiscal 2009 year with minimal revenue, CTT's 2010 revenue promises to be significantly higher, catapulting the company back to profitability. (CTT could see over 300% Quarter to Quarter sales growth from last quarter to this quarter).
It is just during this "sweet spot" time period, when a company basically goes from pre-significant revenue to substantial revenue growth, that an early investor realizes the quickest and best investment return. Investors of Integra Life Sciences (Nasdaq:IART), Affymetrix Inc. (Nasdaq: AFFX) and Cantel Medical (NYSE:CMN) all have benefited from their early recognition that significant revenues were coming from the introduction of a new medical device.
When will CTT report the first of the substantial revenues from its pain management device? By December 15.
But, first, here are a few quick investment highlights for those attention challenged investors:
CTT has only 10.12 Million shares outstanding, giving the company a market cap of only $20.5 Million
Five (5) corporate insiders--the CEO and four directors-- added to their CTT stock positions two weeks ago
Institutional Ownership (mutual and pension funds and money managers) of CTT has risen to 8.9% of the shares outstanding
Company signed a contract with a U.S. distributor which brings over $1 Million in payments over the next 8 months (from August, 2009)
A sales contract announced last month obligates the customer to purchase a minimum of 20 of CTT's pain therapy medical devices over the next 13 months
CTT shipped 17 units last quarter with another 53 units on order and to be shipped most likely in this quarter (ending Jan. 31, 2010)--which would represent a 311% quarter to quarter growth in sales
Clinical data from patients suffering from Chemotherapy-Induced Peripheral Neurapathy (CIPN) that use CTT's medical device is expected soon, offering more media coverage opportunities for the company
What is this new medical technology? CTT's proprietary Calmare TT medical device is for the treatment of chronic pain and the revenues are just beginning to come in. CTT's 2009 fiscal year ended July 31, with revenue from only one medical device unit booked for the entire year. However, the very next quarter (first quarter, 2010 ended Oct. 31) the company announced orders for 70 units with revenue from 17 units that were shipped to be reported in that first quarter. And the first quarter, 2010 financials will be filed by December 15. The remaining 53 units already ordered, but yet to be shipped, may all ship in the current quarter.
As the company expands its marketing push with the recent announcement of the retention of a RF Binder, a Public Relations firm focused on the healthcare industry, CTT is expected to announce more orders, both domestically and internationally. CTT will not be an undiscovered stock for much longer. The company is also expecting clinical data very soon from a study being conducted by the influential Massey Center, a National Cancer Institute- designated Cancer Center (www.massey.vcu.edu/discover/?pid=1900).
The Pain Management systems utilizes a biophysical rather than a biochemical approach, through the use of a multi-processor to simultaneously treat multiple pain areas by applying surface electrodes to the skin. The device has European CE mark certification which is necessary for any medical device to be distributed and sold throughout Europe and makes it eligible for approval for distribution and sales in many other global markets. The all-important FDA approval is just beginning to impact not only sales in the U.S., but also the overseas markets that often await our FDA's verdict.
In July 2009, CTT signed an agreement with Innovative Medical Therapies, Inc. (IMS) granting them exclusive distribution rights to CTT's pain therapy medical device in the United States and related territories excluding the Department of Defense and Veteran's Administration, which another distributor is already in place. The IMS contract provides for minimum monthly cash payments to CTT totaling over $1 million for the first eight months. These minimum monthly payments increase each year throughout the term of the agreement with, for example, the fourth year minimum payments reaching $9 million and eighth year minimum payments of $21 million. IMS will receive shipments of CTT's pain therapy medical device in return for these payments
Cognizant of the difficult economy, CTT has an agreement with Americorp Financial, LLC (AFS) to provide financing of sales of the pain therapy medical device for 24 - 60 month lease terms to hospitals, clinics and medical practices in the U.S. CTT will receive the full retail sales price of the device upon execution of each lease with AFS holding the lease. Basically, with the lease option, most potential CalmareTT customers can easily afford the medical device.
What makes CTT even more intriguing is the very real possibilty for positive surprises beyond the revenue ramp up already happening with the company's Calmare TT device. Competitive Technologies' immediate revenue generator may be the Calmare TT, but the company has the potential to receive milestone payments and royalties from a number of other licensed technologies:
Nanotechnology bone cement biomaterial with a broad range of potential applications, including dental, spinal and other bone related applications. Exclusively licensed by CTT to Soteira Inc. for human spinal applications (a private company which has received $23 Million from its VC partner over the past 15 months);
Sunless tanning agent, a skin-pigment enhancer being researched as a skin cancer preventative, and therapeutic for vitiligo, albinism and psoriasis, CTT exclusively licensed the technology to Clinuvel Pharmaceuticals, Ltd. (Australia);
CTT has a 50/50 joint venture with XION Corporation for the research, development and commercialization of CTT's patented melanocortin analogue compounds which have shown potential in treating sexual dysfunction and obesity
Lupus Diagnostic and Monitoring technology, a cost-effective scalable testing platform used to detect and monitor the autoimmune disease, Lupus
Encryption technology that operates at high speeds with low memory requirements to secure applications used on the Internet, telecommunications, smart cards and e-commerce;
Video and audio signal processing technology licensed in the Motion Picture Electronics Group visual patent portfolio pool (MPEG 4 Visual), and used in streaming video products for personal computers and wireless devices, including mobile phones;
Structural Steel Fissure Detection Paint contains a built-in, self-activating, crack-indicating or warning capability effective coincident with application of the paint to the structure, and requiring minimum training for its use.
In summary, Competitive Technologies can be considered an undiscovered investment idea for those willing to invest prior to the broad dissemination of the unfolding rapid revenue growth to be seen over the next year. CTT currently has a very low average daily trading volume, which does dissuade some investors from participating initially. But, as the saying goes, "Higher volume begets even higher volume" as the investment world discovers an undervalued investment story. Judging by the recent increases in institutional ownership (including one capital management firm, Prescott Group, initiating a position with 312,000 shares purchased), the point of CTT's discovery by the investment world-at-large may be at hand.
Long CTT
Tags: IART, AFFX, RDNT, BDX, CMN, IRIX, VVUS, Medical Technology, Mewdical Devices, Healthcare, Life Sciences
Nov 18 12:58 pm
Reference Link: http://seekingalpha.com/author/david-greene/instablog
Thanks. And check this one (CTT) out from seeking alpha overnight:
CTT's Pain Mangement Device Sales to Result in Positive Surprise in 10Q (Filing Expected by Dec. 15)
Competitive Technologies, Inc. (NYSE Amex: CTT) trading at $2.03 as of 17 Nov.. may be poised to report a rapidly increasing revenue stream from their non-invasive chronic pain management medical device (Calmare TT) which received 501-k clearance from the FDA for marketing in the US recently. Compared to a Fiscal 2009 year with minimal revenue, CTT's 2010 revenue promises to be significantly higher, catapulting the company back to profitability. (CTT could see over 300% Quarter to Quarter sales growth from last quarter to this quarter).
It is just during this "sweet spot" time period, when a company basically goes from pre-significant revenue to substantial revenue growth, that an early investor realizes the quickest and best investment return. Investors of Integra Life Sciences (Nasdaq:IART), Affymetrix Inc. (Nasdaq: AFFX) and Cantel Medical (NYSE:CMN) all have benefited from their early recognition that significant revenues were coming from the introduction of a new medical device.
When will CTT report the first of the substantial revenues from its pain management device? By December 15.
But, first, here are a few quick investment highlights for those attention challenged investors:
CTT has only 10.12 Million shares outstanding, giving the company a market cap of only $20.5 Million
Five (5) corporate insiders--the CEO and four directors-- added to their CTT stock positions two weeks ago
Institutional Ownership (mutual and pension funds and money managers) of CTT has risen to 8.9% of the shares outstanding
Company signed a contract with a U.S. distributor which brings over $1 Million in payments over the next 8 months (from August, 2009)
A sales contract announced last month obligates the customer to purchase a minimum of 20 of CTT's pain therapy medical devices over the next 13 months
CTT shipped 17 units last quarter with another 53 units on order and to be shipped most likely in this quarter (ending Jan. 31, 2010)--which would represent a 311% quarter to quarter growth in sales
Clinical data from patients suffering from Chemotherapy-Induced Peripheral Neurapathy (CIPN) that use CTT's medical device is expected soon, offering more media coverage opportunities for the company
What is this new medical technology? CTT's proprietary Calmare TT medical device is for the treatment of chronic pain and the revenues are just beginning to come in. CTT's 2009 fiscal year ended July 31, with revenue from only one medical device unit booked for the entire year. However, the very next quarter (first quarter, 2010 ended Oct. 31) the company announced orders for 70 units with revenue from 17 units that were shipped to be reported in that first quarter. And the first quarter, 2010 financials will be filed by December 15. The remaining 53 units already ordered, but yet to be shipped, may all ship in the current quarter.
As the company expands its marketing push with the recent announcement of the retention of a RF Binder, a Public Relations firm focused on the healthcare industry, CTT is expected to announce more orders, both domestically and internationally. CTT will not be an undiscovered stock for much longer. The company is also expecting clinical data very soon from a study being conducted by the influential Massey Center, a National Cancer Institute- designated Cancer Center (www.massey.vcu.edu/discover/?pid=1900).
The Pain Management systems utilizes a biophysical rather than a biochemical approach, through the use of a multi-processor to simultaneously treat multiple pain areas by applying surface electrodes to the skin. The device has European CE mark certification which is necessary for any medical device to be distributed and sold throughout Europe and makes it eligible for approval for distribution and sales in many other global markets. The all-important FDA approval is just beginning to impact not only sales in the U.S., but also the overseas markets that often await our FDA's verdict.
In July 2009, CTT signed an agreement with Innovative Medical Therapies, Inc. (IMS) granting them exclusive distribution rights to CTT's pain therapy medical device in the United States and related territories excluding the Department of Defense and Veteran's Administration, which another distributor is already in place. The IMS contract provides for minimum monthly cash payments to CTT totaling over $1 million for the first eight months. These minimum monthly payments increase each year throughout the term of the agreement with, for example, the fourth year minimum payments reaching $9 million and eighth year minimum payments of $21 million. IMS will receive shipments of CTT's pain therapy medical device in return for these payments
Cognizant of the difficult economy, CTT has an agreement with Americorp Financial, LLC (AFS) to provide financing of sales of the pain therapy medical device for 24 - 60 month lease terms to hospitals, clinics and medical practices in the U.S. CTT will receive the full retail sales price of the device upon execution of each lease with AFS holding the lease. Basically, with the lease option, most potential CalmareTT customers can easily afford the medical device.
What makes CTT even more intriguing is the very real possibilty for positive surprises beyond the revenue ramp up already happening with the company's Calmare TT device. Competitive Technologies' immediate revenue generator may be the Calmare TT, but the company has the potential to receive milestone payments and royalties from a number of other licensed technologies:
Nanotechnology bone cement biomaterial with a broad range of potential applications, including dental, spinal and other bone related applications. Exclusively licensed by CTT to Soteira Inc. for human spinal applications (a private company which has received $23 Million from its VC partner over the past 15 months);
Sunless tanning agent, a skin-pigment enhancer being researched as a skin cancer preventative, and therapeutic for vitiligo, albinism and psoriasis, CTT exclusively licensed the technology to Clinuvel Pharmaceuticals, Ltd. (Australia);
CTT has a 50/50 joint venture with XION Corporation for the research, development and commercialization of CTT's patented melanocortin analogue compounds which have shown potential in treating sexual dysfunction and obesity
Lupus Diagnostic and Monitoring technology, a cost-effective scalable testing platform used to detect and monitor the autoimmune disease, Lupus
Encryption technology that operates at high speeds with low memory requirements to secure applications used on the Internet, telecommunications, smart cards and e-commerce;
Video and audio signal processing technology licensed in the Motion Picture Electronics Group visual patent portfolio pool (MPEG 4 Visual), and used in streaming video products for personal computers and wireless devices, including mobile phones;
Structural Steel Fissure Detection Paint contains a built-in, self-activating, crack-indicating or warning capability effective coincident with application of the paint to the structure, and requiring minimum training for its use.
In summary, Competitive Technologies can be considered an undiscovered investment idea for those willing to invest prior to the broad dissemination of the unfolding rapid revenue growth to be seen over the next year. CTT currently has a very low average daily trading volume, which does dissuade some investors from participating initially. But, as the saying goes, "Higher volume begets even higher volume" as the investment world discovers an undervalued investment story. Judging by the recent increases in institutional ownership (including one capital management firm, Prescott Group, initiating a position with 312,000 shares purchased), the point of CTT's discovery by the investment world-at-large may be at hand.
Long CTT
Tags: IART, AFFX, RDNT, BDX, CMN, IRIX, VVUS, Medical Technology, Mewdical Devices, Healthcare, Life Sciences
Nov 18 12:58 pm
Reference Link: http://seekingalpha.com/author/david-greene/instablog
CTT - Great new breakout prediction and coverage of CTT from seekingalpha.com:
CTT's Pain Mangement Device Sales to Result in Positive Surprise in 10Q (Filing Expected by Dec. 15)
Competitive Technologies, Inc. (NYSE Amex: CTT) trading at $2.03 as of 17 Nov.. may be poised to report a rapidly increasing revenue stream from their non-invasive chronic pain management medical device (Calmare TT) which received 501-k clearance from the FDA for marketing in the US recently. Compared to a Fiscal 2009 year with minimal revenue, CTT's 2010 revenue promises to be significantly higher, catapulting the company back to profitability. (CTT could see over 300% Quarter to Quarter sales growth from last quarter to this quarter).
It is just during this "sweet spot" time period, when a company basically goes from pre-significant revenue to substantial revenue growth, that an early investor realizes the quickest and best investment return. Investors of Integra Life Sciences (Nasdaq:IART), Affymetrix Inc. (Nasdaq: AFFX) and Cantel Medical (NYSE:CMN) all have benefited from their early recognition that significant revenues were coming from the introduction of a new medical device.
When will CTT report the first of the substantial revenues from its pain management device? By December 15.
But, first, here are a few quick investment highlights for those attention challenged investors:
CTT has only 10.12 Million shares outstanding, giving the company a market cap of only $20.5 Million
Five (5) corporate insiders--the CEO and four directors-- added to their CTT stock positions two weeks ago
Institutional Ownership (mutual and pension funds and money managers) of CTT has risen to 8.9% of the shares outstanding
Company signed a contract with a U.S. distributor which brings over $1 Million in payments over the next 8 months (from August, 2009)
A sales contract announced last month obligates the customer to purchase a minimum of 20 of CTT's pain therapy medical devices over the next 13 months
CTT shipped 17 units last quarter with another 53 units on order and to be shipped most likely in this quarter (ending Jan. 31, 2010)--which would represent a 311% quarter to quarter growth in sales
Clinical data from patients suffering from Chemotherapy-Induced Peripheral Neurapathy (CIPN) that use CTT's medical device is expected soon, offering more media coverage opportunities for the company
What is this new medical technology? CTT's proprietary Calmare TT medical device is for the treatment of chronic pain and the revenues are just beginning to come in. CTT's 2009 fiscal year ended July 31, with revenue from only one medical device unit booked for the entire year. However, the very next quarter (first quarter, 2010 ended Oct. 31) the company announced orders for 70 units with revenue from 17 units that were shipped to be reported in that first quarter. And the first quarter, 2010 financials will be filed by December 15. The remaining 53 units already ordered, but yet to be shipped, may all ship in the current quarter.
As the company expands its marketing push with the recent announcement of the retention of a RF Binder, a Public Relations firm focused on the healthcare industry, CTT is expected to announce more orders, both domestically and internationally. CTT will not be an undiscovered stock for much longer. The company is also expecting clinical data very soon from a study being conducted by the influential Massey Center, a National Cancer Institute- designated Cancer Center (www.massey.vcu.edu/discover/?pid=1900).
The Pain Management systems utilizes a biophysical rather than a biochemical approach, through the use of a multi-processor to simultaneously treat multiple pain areas by applying surface electrodes to the skin. The device has European CE mark certification which is necessary for any medical device to be distributed and sold throughout Europe and makes it eligible for approval for distribution and sales in many other global markets. The all-important FDA approval is just beginning to impact not only sales in the U.S., but also the overseas markets that often await our FDA's verdict.
In July 2009, CTT signed an agreement with Innovative Medical Therapies, Inc. (IMS) granting them exclusive distribution rights to CTT's pain therapy medical device in the United States and related territories excluding the Department of Defense and Veteran's Administration, which another distributor is already in place. The IMS contract provides for minimum monthly cash payments to CTT totaling over $1 million for the first eight months. These minimum monthly payments increase each year throughout the term of the agreement with, for example, the fourth year minimum payments reaching $9 million and eighth year minimum payments of $21 million. IMS will receive shipments of CTT's pain therapy medical device in return for these payments
Cognizant of the difficult economy, CTT has an agreement with Americorp Financial, LLC (AFS) to provide financing of sales of the pain therapy medical device for 24 - 60 month lease terms to hospitals, clinics and medical practices in the U.S. CTT will receive the full retail sales price of the device upon execution of each lease with AFS holding the lease. Basically, with the lease option, most potential CalmareTT customers can easily afford the medical device.
What makes CTT even more intriguing is the very real possibilty for positive surprises beyond the revenue ramp up already happening with the company's Calmare TT device. Competitive Technologies' immediate revenue generator may be the Calmare TT, but the company has the potential to receive milestone payments and royalties from a number of other licensed technologies:
Nanotechnology bone cement biomaterial with a broad range of potential applications, including dental, spinal and other bone related applications. Exclusively licensed by CTT to Soteira Inc. for human spinal applications (a private company which has received $23 Million from its VC partner over the past 15 months);
Sunless tanning agent, a skin-pigment enhancer being researched as a skin cancer preventative, and therapeutic for vitiligo, albinism and psoriasis, CTT exclusively licensed the technology to Clinuvel Pharmaceuticals, Ltd. (Australia);
CTT has a 50/50 joint venture with XION Corporation for the research, development and commercialization of CTT's patented melanocortin analogue compounds which have shown potential in treating sexual dysfunction and obesity
Lupus Diagnostic and Monitoring technology, a cost-effective scalable testing platform used to detect and monitor the autoimmune disease, Lupus
Encryption technology that operates at high speeds with low memory requirements to secure applications used on the Internet, telecommunications, smart cards and e-commerce;
Video and audio signal processing technology licensed in the Motion Picture Electronics Group visual patent portfolio pool (MPEG 4 Visual), and used in streaming video products for personal computers and wireless devices, including mobile phones;
Structural Steel Fissure Detection Paint contains a built-in, self-activating, crack-indicating or warning capability effective coincident with application of the paint to the structure, and requiring minimum training for its use.
In summary, Competitive Technologies can be considered an undiscovered investment idea for those willing to invest prior to the broad dissemination of the unfolding rapid revenue growth to be seen over the next year. CTT currently has a very low average daily trading volume, which does dissuade some investors from participating initially. But, as the saying goes, "Higher volume begets even higher volume" as the investment world discovers an undervalued investment story. Judging by the recent increases in institutional ownership (including one capital management firm, Prescott Group, initiating a position with 312,000 shares purchased), the point of CTT's discovery by the investment world-at-large may be at hand.
Long CTT
Tags: IART, AFFX, RDNT, BDX, CMN, IRIX, VVUS, Medical Technology, Mewdical Devices, Healthcare, Life Sciences
Nov 18 12:58 pm
Reference Link: http://seekingalpha.com/author/david-greene/instablog
Great coverage and recommendation of CTT from SeekingAlpha.com:
CTT's Pain Mangement Device Sales to Result in Positive Surprise in 10Q (Filing Expected by Dec. 15)
Competitive Technologies, Inc. (NYSE Amex: CTT) trading at $2.03 as of 17 Nov.. may be poised to report a rapidly increasing revenue stream from their non-invasive chronic pain management medical device (Calmare TT) which received 501-k clearance from the FDA for marketing in the US recently. Compared to a Fiscal 2009 year with minimal revenue, CTT's 2010 revenue promises to be significantly higher, catapulting the company back to profitability. (CTT could see over 300% Quarter to Quarter sales growth from last quarter to this quarter).
It is just during this "sweet spot" time period, when a company basically goes from pre-significant revenue to substantial revenue growth, that an early investor realizes the quickest and best investment return. Investors of Integra Life Sciences (Nasdaq:IART), Affymetrix Inc. (Nasdaq: AFFX) and Cantel Medical (NYSE:CMN) all have benefited from their early recognition that significant revenues were coming from the introduction of a new medical device.
When will CTT report the first of the substantial revenues from its pain management device? By December 15.
But, first, here are a few quick investment highlights for those attention challenged investors:
CTT has only 10.12 Million shares outstanding, giving the company a market cap of only $20.5 Million
Five (5) corporate insiders--the CEO and four directors-- added to their CTT stock positions two weeks ago
Institutional Ownership (mutual and pension funds and money managers) of CTT has risen to 8.9% of the shares outstanding
Company signed a contract with a U.S. distributor which brings over $1 Million in payments over the next 8 months (from August, 2009)
A sales contract announced last month obligates the customer to purchase a minimum of 20 of CTT's pain therapy medical devices over the next 13 months
CTT shipped 17 units last quarter with another 53 units on order and to be shipped most likely in this quarter (ending Jan. 31, 2010)--which would represent a 311% quarter to quarter growth in sales
Clinical data from patients suffering from Chemotherapy-Induced Peripheral Neurapathy (CIPN) that use CTT's medical device is expected soon, offering more media coverage opportunities for the company
What is this new medical technology? CTT's proprietary Calmare TT medical device is for the treatment of chronic pain and the revenues are just beginning to come in. CTT's 2009 fiscal year ended July 31, with revenue from only one medical device unit booked for the entire year. However, the very next quarter (first quarter, 2010 ended Oct. 31) the company announced orders for 70 units with revenue from 17 units that were shipped to be reported in that first quarter. And the first quarter, 2010 financials will be filed by December 15. The remaining 53 units already ordered, but yet to be shipped, may all ship in the current quarter.
As the company expands its marketing push with the recent announcement of the retention of a RF Binder, a Public Relations firm focused on the healthcare industry, CTT is expected to announce more orders, both domestically and internationally. CTT will not be an undiscovered stock for much longer. The company is also expecting clinical data very soon from a study being conducted by the influential Massey Center, a National Cancer Institute- designated Cancer Center (www.massey.vcu.edu/discover/?pid=1900).
The Pain Management systems utilizes a biophysical rather than a biochemical approach, through the use of a multi-processor to simultaneously treat multiple pain areas by applying surface electrodes to the skin. The device has European CE mark certification which is necessary for any medical device to be distributed and sold throughout Europe and makes it eligible for approval for distribution and sales in many other global markets. The all-important FDA approval is just beginning to impact not only sales in the U.S., but also the overseas markets that often await our FDA's verdict.
In July 2009, CTT signed an agreement with Innovative Medical Therapies, Inc. (IMS) granting them exclusive distribution rights to CTT's pain therapy medical device in the United States and related territories excluding the Department of Defense and Veteran's Administration, which another distributor is already in place. The IMS contract provides for minimum monthly cash payments to CTT totaling over $1 million for the first eight months. These minimum monthly payments increase each year throughout the term of the agreement with, for example, the fourth year minimum payments reaching $9 million and eighth year minimum payments of $21 million. IMS will receive shipments of CTT's pain therapy medical device in return for these payments
Cognizant of the difficult economy, CTT has an agreement with Americorp Financial, LLC (AFS) to provide financing of sales of the pain therapy medical device for 24 - 60 month lease terms to hospitals, clinics and medical practices in the U.S. CTT will receive the full retail sales price of the device upon execution of each lease with AFS holding the lease. Basically, with the lease option, most potential CalmareTT customers can easily afford the medical device.
What makes CTT even more intriguing is the very real possibilty for positive surprises beyond the revenue ramp up already happening with the company's Calmare TT device. Competitive Technologies' immediate revenue generator may be the Calmare TT, but the company has the potential to receive milestone payments and royalties from a number of other licensed technologies:
Nanotechnology bone cement biomaterial with a broad range of potential applications, including dental, spinal and other bone related applications. Exclusively licensed by CTT to Soteira Inc. for human spinal applications (a private company which has received $23 Million from its VC partner over the past 15 months);
Sunless tanning agent, a skin-pigment enhancer being researched as a skin cancer preventative, and therapeutic for vitiligo, albinism and psoriasis, CTT exclusively licensed the technology to Clinuvel Pharmaceuticals, Ltd. (Australia);
CTT has a 50/50 joint venture with XION Corporation for the research, development and commercialization of CTT's patented melanocortin analogue compounds which have shown potential in treating sexual dysfunction and obesity
Lupus Diagnostic and Monitoring technology, a cost-effective scalable testing platform used to detect and monitor the autoimmune disease, Lupus
Encryption technology that operates at high speeds with low memory requirements to secure applications used on the Internet, telecommunications, smart cards and e-commerce;
Video and audio signal processing technology licensed in the Motion Picture Electronics Group visual patent portfolio pool (MPEG 4 Visual), and used in streaming video products for personal computers and wireless devices, including mobile phones;
Structural Steel Fissure Detection Paint contains a built-in, self-activating, crack-indicating or warning capability effective coincident with application of the paint to the structure, and requiring minimum training for its use.
In summary, Competitive Technologies can be considered an undiscovered investment idea for those willing to invest prior to the broad dissemination of the unfolding rapid revenue growth to be seen over the next year. CTT currently has a very low average daily trading volume, which does dissuade some investors from participating initially. But, as the saying goes, "Higher volume begets even higher volume" as the investment world discovers an undervalued investment story. Judging by the recent increases in institutional ownership (including one capital management firm, Prescott Group, initiating a position with 312,000 shares purchased), the point of CTT's discovery by the investment world-at-large may be at hand.
Long CTT
Tags: IART, AFFX, RDNT, BDX, CMN, IRIX, VVUS, Medical Technology, Mewdical Devices, Healthcare, Life Sciences
Nov 18 12:58 pm
Reference Link: http://seekingalpha.com/author/david-greene/instablog
Things are strangely quiet on the CTT front today. And, note that there are only 100 sh bid at 2.03. We need some news to wake this thing up.
Suspicious of what? Shorts? Paid bashers? Just wondering.
No. Buying opportunity. I neither bristled nor brushed it off, but rather just doubled up with another 50,000 shares at .062. Now, average PPS is .067.
There may quite possibly be news on the horizon, but you are mentioning activity on the AXTG Board over at yahoo finance? That is the last place I would go to learn anything about AXTG. That board is an absolute joke. I posted over there for a while earlier this year, but eventually concluded it was a total waste of time. Sheer and utter nonsense over there. I will simply await likely positive developments out of the comapny and bide my time patiently. But, I hope and believe you may be right about "something stirring" as I understand the company has been working very hard on several positive fronts of late heading into 2010.
At first glance today may look like a bad day for UTRM thus far. But, I look at it this way - the stock may be down, but the total $$ volume of the selling is less than $5,000. Big deal. That is nothing, and it means nothing in the larger scheme of things for UTRM going forward.
Good point. And, as long as the major bidder is that level it is hard to get much up volume.
HH: Your/Our day will come!!!
Thanks. that's great. And funny too. I was also trying to be somewhat funny. And, I will continue to add to my new position in CTT as warranted. I think that at some point in the not to distant future, we will look back to this time period as a fabulous buying opportunity.
Great stuff. Thanks!
I think I am becoming a bad influence here, and that I should quit buying the stock. I decided to add to my initial position this morning when the stock dropped back, and I bought more stock between the spread. But, as soon as my trade went through the bid and PPS both dropped right away.
Note that the vast majority of the volume today has come on the way back up since the stock hit it's low early this morning at .15 The selldown to the .15-.16 range was on very little volume relatively speaking. Not trying to diminish the dissappointment of the drop in PPS, but see some positive aspect here in the trade up on substantially higher volume than traded on the way down.
Thanks Eagle. These stocks always trade funny.
World Market Media is a very good outlet for news to reach new potential investors. That is the likely reason for the volume spike on Friday. The million+ share volume is huge, but let's remember that is still less than $80,000 at this price. Think what this thing can and will do when we get enough cummulative buying to bring several hundred thousand $$$ into the stock in a day.